Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and 26 bp insertion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ELL2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ELL2 also known as Eleven Nineteen Lysine-rich Leukemia 2 is a protein involved in transcriptional regulation. This protein has a molecular mass of approximately 76 kDa. ELL2 is expressed in various tissues including both lymphoid and non-lymphoid origins. It functions as an elongation factor for RNA polymerase II modulating the rate of transcription elongation by directly interacting with the transcription machinery.
Biological function summary
ELL2 plays a significant role in RNA processing and maturation. It is a part of the ELL complex and works alongside other proteins that facilitate the transition from transcription initiation to elongation. By promoting RNA synthesis and elongation efficiency ELL2 is linked with gene expression regulation particularly within the adaptive immune system. This protein helps in optimizing the output of genes active in immune cells contributing to the functionality and differentiation of these cells.
Pathways
ELL2 participates actively in the transcription regulation pathway and its interaction with RNA polymerase II. The protein influences gene expression regulation by enhancing transcriptional elongation. ELL2 is also involved in pathways associated with the immunoglobulin production process. It interacts with other proteins such as ELL1 and pTEFb which further coordinate the elongation steps of transcription thereby impacting overall gene expression in immune-related pathways.
ELL2 associates with multiple myeloma and immunodeficiency disorders. Its dysfunction can impact immunoglobulin transcription in plasma cells potentially leading to aberrant immunoglobulin production—an element in the pathogenesis of multiple myeloma. The association of ELL2 with RNA polymerase II and its partners like pTEFb sheds light on its role in these conditions as faulty regulation of transcription elongation can lead to abnormal cell proliferation and survival characteristic of certain cancers and immune disorders.
